Program
Propylene Glycol
Also written as “Propylene Glycol (0.6%)”, “Nanodrop®” and “Propylene Glycol, 0.6% eye drops”.
Its studies are mostly in Dry Eye Syndromes, led by 3 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Alcon | 10 open or running | no phasesince Oct 18, 2013 | Oct 18, 2013 | none ahead |
| Andover Research Eye Institute | 11 open or running | phase 4since Jun 24, 2026 | Jun 24, 2026 | none ahead |
| Laboratorios Sophia S.A de C.V. | 10 open or running | phase 2since Sep 30, 2019 | Sep 30, 2019 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 18, 2013First study: no phase study in Dry Eye SyndromesNew to AlconAlcon · NCT01967147 · 279 enrolled
- Sep 30, 2019Laboratorios Sophia S.A de C.V.'s first study: phase 2 study in Dry Eye SyndromesNew to Laboratorios Sophia S.A de C.V.Laboratorios Sophia S.A de C.V. · NCT04111965 · 126 enrolled · Mexico
- Jun 24, 2026Andover Research Eye Institute's first study: phase 4 study in Dry Eye SyndromesNew to Andover Research Eye InstituteAndover Research Eye Institute · NCT07676084 · 60 planned · United States
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07676084Dry Eye Syndromes · United States | 4 | Recruiting | Andover Research Eye Institute | Oct 2026 | 60 |
| NCT04111965Dry Eye Syndromes · Mexico | 2 | Completed | Laboratorios Sophia S.A de C.V. | Dec 10, 2021 | 126 |
| NCT01967147Dry Eye Syndromes | – | Completed | Alcon | Jan 2015 | 279 |
How it is read
Names in the registry
- “Propylene Glycol (0.6%)”, 1 entry
- “Nanodrop®”, 1 entry
- “Propylene Glycol, 0.6% eye drops”, 1 entry
Conditions, from the studies’ own filings
- Dry Eye Syndromes, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.